Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to dronabinol: Marinol


one of the major active substances in cannabis, used to treat nausea and vomiting in antineoplastic therapy and to treat anorexia associated with weight loss in acquired immunodeficiency syndrome; it is subject to abuse because of its psychotomimetic activity.



Pharmacologic class: Cannabinoid

Therapeutic class: Antiemetic

Controlled substance III

Pregnancy risk category B


Unknown. May exert antiemetic effect by inhibiting vomiting control mechanism in medulla oblongata.


Capsules: 2.5 mg, 5 mg, 10 mg

Indications and dosages

Prevention of nausea and vomiting caused by chemotherapy

Adults and children: Initially, 5 mg/m2 P.O. 1 to 3 hours before chemotherapy. Repeat dose q 2 to 4 hours after chemotherapy, up to four to six doses per day. If 5-mg/m2 dose is ineffective and patient has no significant adverse reactions, dosage may be increased in increments of 2.5 mg/m2 to a maximum dosage of 15 mg/m2.

Appetite stimulant

Adults and children: Initially, 2.5 mg P.O. b.i.d. May reduce dosage to 2.5 mg/day given as a single evening or bedtime dose. Maximum dosage is 10 mg P.O. b.i.d.


• Hypersensitivity to cannabinoids or sesame oil
• Breastfeeding


Use cautiously in:
• hypertension, heart disease, bipolar disorder, schizophrenia, drug abuse, seizures
• pregnant patients.


• When used to stimulate appetite, give before lunch and dinner.

Adverse reactions

CNS: drowsiness, anxiety, impaired coordination, irritability, depression, headache, hallucinations, memory loss, paresthesia, ataxia, paranoia, disorientation, nightmares, speech difficulties, syncope, suicidal ideation

CV: tachycardia, hypotension, hypertension

EENT: visual disturbances, tinnitus

GI: dry mouth

Skin: facial flushing, diaphoresis


Drug-drug.Anticholinergics, antihistamines, tricyclic antidepressants: increased tachycardia and hypertension

CNS depressants: increased CNS depression

Ritonavir: increased dronabinol blood level and risk of toxicity

Drug-behaviors.Alcohol use: increased CNS depression

Patient monitoring

• Monitor vital signs for hypotension and tachycardia.

Check for adverse CNS reactions. Report significant depression, paranoid reaction, or emotional lability.
• Monitor nutritional status and hydration.

Patient teaching

• Teach patient about drug's significant adverse CNS and cardiovascular effects. Emphasize that he should take it only as prescribed and needed.

Advise patient (and significant other) to immediately report depression, suicidal thoughts, paranoid reactions, seizures, and other serious CNS reactions.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.


A major psychoactive substance present in Cannabis sativa, used therapeutically as an antinauseant to control the nausea and vomiting associated with cancer chemotherapy.
See also: tetrahydrocannabinols.


/dro·nab·i·nol/ (dro-nab´in-ol) one of the major active substances in cannabis, used as an antiemetic for cancer chemotherapy and anorexia and weight loss in AIDS; it is subject to abuse because of its psychotomimetic activity.


A synthetic form of THC, the principal psychoactive substance in Cannabis sativa, used therapeutically to control nausea and vomiting associated with cancer chemotherapy and to treat anorexia and weight loss in patients with AIDS.


an oral antiemetic that is a synthetic derivative of THC, the principal psychotropic constituent of marijuana.
indications It is prescribed for the treatment of refractory nausea and vomiting caused by cancer chemotherapy.
contraindications It should not be given to persons with known hypersensitivity to the drug or to tetrahydrocannabinol, its active ingredient.
adverse effects Among adverse effects reported are drowsiness, dizziness, impaired coordination, and hallucinations. Dronabinol is a Schedule III controlled substance with a high potential for abuse. It can produce both physical and psychological dependence. It is not recommended for patients who are using a central nervous system depressant or other psychoactive drugs.


Marinol® A synthetic Δ9THC-tetrahydrocannabinol, an active ingredient of marijuana, which may be used to manage glaucoma, pain, N&V, anorexia, wasting linked to chemotherapy, AIDS Adverse effect Drowsiness, confusion, poor coordination. See Marijuana, THC.


A major psychoactive substance present in Cannabis sativa; used therapeutically as an antinauseant to control the queasiness and vomiting associated with cancer chemotherapy.
See also: tetrahydrocannabinols
References in periodicals archive ?
Patients using nabilone or dronabinol reported the longest time before first onset of effect, likely due to the delay in GI absorption, resulting in similar scores compared to cannabis taken in food or as a tincture.
Patients were given either dronabinol capsules or identical looking placebo capsules for three weeks.
A total of 61 patients (79%) in the dronabinol group completed the 8-week maintenance phase, compared with 47 (59%) of the placebo group.
In a pilot Phase 2 study, Pier demonstrated that dronabinol reduced measures of obstructive sleep apnea and excessive daytime sleepiness when administered once-a-day before bedtime for three weeks.
This includes license agreements for such products as Immulina, an algal-derived immunostimulant formulation, and dronabinol hemisuccinate, a plant-derived anti-emetic which can be administered orally or in suppository form to prevent nausea and vomiting in cancer patients.
We are pleased that Unimed will be partnering with us to develop this inhaleable dronabinol, as they have the history and knowledge with this product and its patient base," said Ajit Gill, president and CEO of Inhale.
0 million, or nearly 80%, from the year ago period, principally driven by limited competition in metoprolol succinate, sumatriptan succinate, meclizine, and dronabinol, as well as the launches of nateglinide and clonidine in the third quarter, and tramadol ER in the fourth quarter 2009.
a subsidiary of Solvay Pharmaceuticals, will develop a metered dose inhaler (MDI) of dronabinol (synthetic delta-9-tetrahydrocannabinol) to be used for multiple indications.